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Fe is an essential component of haem in myoglobin and accounts for 70 % of haemoglobin. The
balance of Fe, unlike that of other metals such as Na or Ca, is regulated solely by gastrointes-
tinal absorption, which itself depends on the bioavailability of Fe in food, i.e. the chemical Fe
species. Factors that maintain Fe homeostasis by modulating Fe transfer through the intestinal
mucosa are found at the luminal, mucosal and systemic levels. Fe deficiency and its conse-
quence, Fe-deficiency anaemia, form the commonest nutritional pathology in pregnant
women. The current gold standard to detect Fe deficiency remains the serum ferritin value. Pre-
viously there was general consensus against parenteral Fe administration, i.e. parenteral Fe was
only recommended for special conditions such as unresponsiveness to oral Fe, intolerance to
oral Fe, severe anaemia, lack of time for therapy etc. However, especially in hospital settings,
clinicians regularly face these conditions but are still worried about reactions that were
described using Fe preparations such as Fe–dextrans. A widely used and safe alternative is
the Fe–sucrose complex, which has become of major interest to prevent functional Fe
deficiency after use of recombinant erythropoietin Numerous reports show the effectiveness
and safety of the Fe–sucrose complex. Good tolerance to this Fe formulation is partly due
to the low allergenic effect of the sucrose complex, partly due to slow release of elementary
Fe from the complex. Accumulation of Fe–sucrose in parenchyma of organs is low compared
with Fe–dextrans or Fe–gluconate, while incorporation into the bone marrow for erythropoiesis
is considerably faster. Oral Fe is only started if haemoglobin levels are below 110 g/l. If levels
fall below 100 g/l or are below 100 g/l at time of diagnosis, parenteral Fe–sucrose is used pri-
marily. In cases of severe anaemia (haemoglobin ,90 g/l) or non-response to parenteral Fe
after 2 weeks, recombinant erythropoietin is considered in combination. By using parenteral
Fe–sucrose in cases of severe Fe deficiency, anaemia during pregnancy is treated efficiently
and safely according to our results and rate of blood transfusion could be reduced considerably
to below 1 % of patients per year.
Iron: Pregnancy: Parenteral
Iron function and requirements
Fe is an essential component of haem in myoglobin and
accounts for 70 % of haemoglobin (Hb). It is thus a key
player in O2 binding and transport. It is also found in
many electron-transferring enzymes in the redox system of
the respiratory chain. Total body Fe in man is 4–5 g. Daily
losses, e.g. in epithelial desquamation from the gastro-
intestinal tract or skin, are small. Excretion in urine, bile
and sweat is negligible (Forth & Rummel, 1992). The
normal daily Fe requirement is thus only 1 mg, increasing
with physiological need, as in growth, pregnancy and
blood loss: an additional 1000 mg Fe is required in preg-
nancy, and 0·5 mg Fe/ml blood loss (Letsky, 1995; Hercberg
et al. 2000).
Iron absorption
The balance of Fe, unlike that of other metals such as Na or
Ca, is regulated solely by gastrointestinal absorption,
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which itself depends on the bioavailability of Fe in food,
i.e. the chemical Fe species. Factors that maintain Fe
homeostasis by modulating Fe transfer through the intes-
tinal mucosa are found at the luminal, mucosal and systemic
levels. The interactions between the various Fe species and
the brush-border membrane are critical to the effectiveness
of absorption.
The speciation of non-haem Fe depends on both dietary
composition and intestinal secretions (Perewusnyk & Funk,
1997). In particular, Fe-binding intestinal mucins prevent
the hydrolysis of Fe and its precipitation at high pH
(Conrad et al. 1991). Parenteral Fe administration circum-
vents this gastrointestinal regulatory mechanism.
Prevalence and consequences of iron deficiency
Fe deficiency and its consequence, Fe-deficiency anaemia,
form the commonest nutritional pathology in pregnant
women (Allen, 1997). The prevalence of Fe-deficiency
anaemia in pregnancy in the developing world is 56
(range 35–75) %, v. 18 % in the developed world. The cor-
responding figures in non-pregnant women are 43 and 12 %
respectively (Cook et al. 1994). The prevalence of Fe
deficiency is much higher. Without adequate Fe sup-
plementation, ferritin falls to subnormal levels towards
the end of pregnancy even in the industrialized nations
(Carriaga et al. 1991; Milman et al. 1994; Letsky, 1995).
Maternal Fe-deficiency anaemia is associated with low
birth-weight and increases in preterm birth rate and peri-
natal mortality (Garn et al. 1981; Murphy et al. 1986); it
may also irreversibly impair fetal neurological develop-
ment (Baynes, 1994). Further consequences include
reduced exercise tolerance, stomatitis (Cook & Lynch,
1981), structural and chemical changes to the hair, nails
and skin (Sato, 1991), and impairment of thermogenesis,
thyroid metabolism and catecholamine turnover (Beard
et al. 1990a,b). Fe deficiency increases the absorption of
other cations, leading to excessive levels of Pb and Al,
with corresponding toxic effects (Baynes, 1994). The
impact on immune function remains unelucidated.
Investigation of iron deficiency
The standard Fe status variables are serum ferritin, trans-
ferrin, Fe, and transferrin saturation, Hb, and the red cell
indices, mean corpuscular Hb, mean corpuscular Hb con-
centration, and mean corpuscular volume, which are all
decreased in Fe-deficiency anaemia. In the absence of
interfering factors, Fe deficiency is defined by a serum
ferritin ,15mg/l, Fe ,11mmol/l and transferrin saturation
,15 %. Pregnancy anaemia is defined by Hb ,110 g/l in
the first or third trimester or ,105 g/l in the second (Cen-
ters for Disease Control and Prevention, 1989).
When applying these guidelines and limit values it is
important to bear in mind that they may reflect factors
other than Fe status. Thus, ferritin is also an acute-phase
protein, i.e. its levels increase independently of Fe status
in fever, acute and chronic inflammation, and rheumatoid
arthritis, as well as in acute or chronic liver disease.
There is increasing debate over the relevance of pregnancy
ferritin levels since they often correlate poorly with the
degree of anaemia and are affected by subclinical infec-
tions (Baynes, 1994; Allen, 1997; Breymann, 2000). Nor
is transferrin an always reliable index, being decreased in
inflammation, infection, malignancy, liver disease, nephro-
tic syndrome and malnutrition, and increased by pregnancy
and oral contraceptives. Serum Fe is likewise decreased by
infection, inflammation, malignancy and vitamin C
deficiency, and increased by transiently increased Fe
absorption, aplastic anaemia, ineffective erythropoiesis
and liver disease, as well as being subject to large diurnal
variation through being replaced several times each day.
These key variables can thus become unreliable during
critical phases in obstetric management, e.g. the postpar-
tum inflammatory response when the cumulative effect of
pregnancy and puerperal blood loss often results in Fe
deficiency demanding correction. A newly-studied vari-
able, the transferrin receptor (TfR) concentration, has
been introduced to diagnose Fe-deficiency anaemia reliably
under these conditions (Punnonen et al. 1997; Krafft et al.
1999; Perewusnyk et al. 1999; Rusia et al. 1999). TfR is a
transmembrane protein present on virtually all cells. Its
concentration depends on the Fe requirements of the cell
and on cell growth (two-thirds of all TfR are found in
red bone marrow). The serum TfR concentration detects
Fe deficiency at the cellular level. Soluble TfR represents
only the detached, extramembranous, transferrin-com-
plexed portion of the receptor. Its levels are proportional
to the total number of receptors in the tissue. These factors
underlie the use of TfR quantitation as a sensitive indicator
of Fe deficiency, unaffected by infection or inflammation,
and independent of sex, age, and pregnancy per se. It
can be used to differentiate between Fe-deficiency anaemia
and the anaemia of chronic disease. It is especially informa-
tive at low ferritin levels when Fe deficiency cannot other-
wise be quantitated. The combination of TfR, ferritin and
Hb provides a complete picture of Fe store and functional
compartment status.
Neopterin, another interesting newly-studied variable,
regulates erythropoietin production by suppressing
expression of the erthyropoietin gene. The serum neopterin
concentration is inversely proportional to the Hb concen-
tration (Schobersberger & Jelkmann, 1995). Neopterin
can thus be used to distinguish between Fe deficiency
and inflammation as the cause of defective Hb synthesis.
General remarks on iron therapy
A healthy diet rich in vitamin C and animal protein, and
poor in phosphates, oxalic acid and fat, helps to prevent
Fe deficiency and supports treatment with Fe preparations.
The goal of therapy is to administer enough Fe to correct
the anaemia and replenish the Fe stores. The advantages
and disadvantages of the various preparations and routes
of administration should be carefully weighed before
selecting the form of therapy.
In the first instance the choice is between oral and par-
enteral therapy. Under normal circumstances oral Fe is
the treatment of choice since it is simple, effective, safe
and cheap. It also relies on the natural mechanism regulat-
ing total body Fe, namely the holo-transferrin and apo-
transferrin receptors determining the Fe content of the
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intestinal cells (Umbreit et al. 1998). However, oral Fe can
cause nausea, malaise, vomiting, pain, diarrhoea, and con-
stipation, resulting in poor compliance. These side effects
can be relieved by co-administration with food, although
this may substantially decrease absorption, particularly of
ferrous preparations. Slow-release preparations of Fe salts
or Fe complexes, e.g. iron(III) polymaltose which interacts
with neither food nor other drugs, help to maximize
absorption and decrease side effects to the placebo level.
The parenteral therapy option is dictated by:
inadequate gastrointestinal iron absorption;
intolerance to the requisite dose of oral iron;
the requirement for emergency supplementation;
contraindication to blood transfusion;
chronic blood loss exceeding the oral replacement potential;
combination with recombinant human erthyropoeitin
Parenteral iron therapy
Parenteral Fe circumvents the natural regulatory mechan-
ism to deliver non-protein-bound Fe. Free Fe is a potential
toxin and/or carcinogen, leading to the production of
hydroxide radicals and stimulating the growth of trans-
formed cells by inhibiting the defence system. It can also
cause changes in cell membrane permeability, and even
cell lysis, via peroxidation of cell membrane lipid. Free
Fe induces so-called O2 toxicity, although is now known
to be pathological only in Fe overload (Danielson et al.
1996). For these reasons parenteral Fe therapy should not
be attempted until complete Fe status has been determined.
The Hb concentration alone is not enough. Once parenteral
therapy has been decided, it is important to choose a suit-
able product and administer it slowly to avoid excessive
blood concentrations of free Fe.
Parenteral iron preparations
Four groups of parenteral preparations are available, classi-
fied according to kinetic (labile v. stable) and thermo-
dynamic (weak v. strong) criteria. They differ essentially
in complex stability, molecular mass, toxicity, histology,
pharmacokinetics and side effects.
The type I complexes include iron dextran and iron dex-
trin, both stable, strong complexes of over 100 000 Da, dis-
playing high structural homogeneity and thus releasing
their Fe only slowly and competitively to endogenous Fe
binding proteins. The Fe enters the reticuloendothelial
system. The half-life of Fe dextran elimination from
plasma is 3–4 d. The Fe binds to transferrin and some
re-enters the plasma, from where it is transported to the
bone marrow and utilized for Hb synthesis. High complex
stability and slow Fe release enable these complexes to be
classed as clinically safe. Side effects from the Fe are
highly unlikely. However, because the complexes have a
very high molecular mass, they may cause allergic reac-
tions in very rare cases. Even low molecular mass dextrans
can react with specific antibodies and provoke an anaphy-
lactic reaction. This danger is avoided by using dextrin
(Danielson, 1998).
Type II includes Fe complexes of intermediate stability
and strength such as iron (III) hydroxide–saccharate com-
plex (iron–sucrose complex: Venoferw, Vifor, St Gallen,
Switzerland), with molecular masses ranging from 30 000
to 100 000 Da, releasing Fe to the endogenous Fe-binding
proteins with a half-life of about 6 h. The Fe is taken up
mainly in the reticuloendothelial system and liver, by trans-
ferrin and apoferritin, and by the spleen and bone marrow.
It is rapidly metabolized and is thus rapidly available for
erythropoiesis. At a recommended therapeutic dose of 1–
4 mg Fe/kg body weight or 100–200 mg Fe/d, injected
slowly or infused with NaCl, the transport system is not
overloaded and Fe ions do not appear. Complex stability
and the Fe distribution profile make this group clinically
safe. Moreover, as the complexes contain no biological
polymers, anaphylactic reactions are highly unlikely
(Danielson et al. 1996; Danielson, 1998; Hoigne´ et al.
1998).
Type III comprises labile and weak Fe complexes with
molecular masses below 50 000 Da. Examples include
iron (III) gluconate, iron (III) citrate and iron (III) sorbitol.
Administration of iron (III) gluconate at the doses used
with types I or II causes severe and extensive liver necro-
sis. Fe is deposited in the reticuloendothelial system, but in
also the parenchyma, leading to radical-generating lipid
peroxidation. Iron (III) citrate and iron (III) sorbitol have
very low molecular mass (about 8700 Da) and are excreted
very rapidly by the kidney. Only a very small amount of Fe
can therefore be transferred to the Fe-binding proteins.
Type IV is a mixture of at least two complexes of differ-
ent classes, releasing Fe to all types of protein so that
quantitative binding to transferrin or apoferritin is possible
only if very small amounts are administered. Excess Fe
is bound to proteins such as albumin and subsequently
metabolized.
Given the lability of type III and IV complexes and their
pattern of Fe distribution, neither can be considered clinic-
ally safe. Toxic reactions can be expected even at low
therapeutic doses, and intravenous use is not recommended
(Danielson et al. 1996; Danielson, 1998; Hoigne´ et al.
1998).
Experience with iron–sucrose complex in the
department of obstetrics, Zurich university hospital
(1992–2000)
Indications for parenteral therapy
The indication in pregnancy was the failure of Fe-
deficiency anaemia (Hb ,100 g/l, ferritin ,15mg/l) to
respond by an increase in either reticulocytes or Hb to
oral Fe (160 mg/d for 2 weeks). This presumed the pre-
treatment exclusion of other causes of anaemia, e.g. haemo-
globinopathy, gastrointestinal bleeding, infections and
vitamin B12 or folate deficiency (Breymann et al. 2001).
In line with WHO criteria (World Health Organization,
1972), the postpartum indication was Hb ,100 g/l after
blood loss within 48 h of delivery (Breymann et al. 1996,
2000). Patients with Hb .10·0 g/l received oral Fe (80–
160 mg/d).
Parenteral iron therapy in obstetrics 5
https:/www.cambridge.org/core/terms. https://doi.org/10.1079/BJN2002577
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 13:43:35, subject to the Cambridge Core terms of use, available at
Administration
Fe-sucrose (Venoferw, Vifor) was administered as either a
bolus (undiluted) or short infusion (in 200 ml Nacl (9 g/l)).
Maximum cumulative doses were 800 mg postpartum
(200 mg/d for 4 d) and 1600 mg in pregnancy (200 mg
twice per week to a target Hb of 110 g/l or for a maximum
of 4 weeks), administered via peripheral catheter over
30 min for short infusions (in-patients) and over 5–
10 min for bolus injections (outpatients).
Results
Safety profile
Over an 8-year period (1992–2000) a total of 500 patients
received a total of 2500 ampoules, each containing the
equivalent of 100 mg elemental Fe. Side-effect rates
(flush (n 4) and rash (n 3)), all on the first day of treatment,
were 1·5 % relative to the total number of patients and
0·36 % relative to the number of ampoules (Breymann,
1998; Hoigne´ et al. 1998). No serious side effects or ana-
phylactoid reactions were observed. In no case did treat-
ment have to be discontinued or blood transfused due to
non-response to treatment.
Pregnancy
Pretreatment mean Hb was 92 (SD 6) g/l (79–99 g/l) and
gestational age 31·5 weeks (20–38 weeks). Mean treatment
duration was 21 d (8–29 d). Both ferritin and transferrin
saturation were clearly pathological at a baseline (7·0 (SD
4·0) mg/l and 6·2 (SD 3·7) % respectively). Hypochromic
red cells levels were markedly elevated: 18·5 (SD 9·3) %.
All variables improved significantly after 2 weeks
(Table 1). Anaemia was corrected in all patients, with a
mean increase in Hb of 19 g/l (significant from day 7,
Fig. 1) and significant increases in mean corpuscular
volume and mean corpuscular Hb. Hypochromic red cells
fell by a mean value of 4·2 %. By the end of treatment,
transferrin saturation and ferritin (also significant from
day 7, Fig. 2) were normal.
Table 1. Response of haemoglobin, red cell indices, transferrin sat-
uration and ferritin to parenteral iron–sucrose complex† in preg-
nancy iron-deficiency anaemia‡
(Mean values and standard deviations for 100 subjects)
Day 0 Day 28
Mean SD Mean SD Normal value
Hb (g/l) 92 6 109** 5 .105
MCV (fl) 79·2 5·7 84·4** 4·4 .80·0
MCH (pg) 24·9 2·4 27·0* 2·1 .29·0
HRC (%) 18·5 9·3 14·3 14·2 ,2·5
Tfsat (%) 6·2 3·7 32·2** 5·4 .20
Ferritin (mg/l) 7·0 4·0 342·0** 119·0 .15
Hb, Haemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular,
hemoglobin; HRC hypochromic red cells; Tfsat, transferrin saturation.
Mean values were significantly different from those at day 0 (paired t test):
*P,0·05, **P,0·01.
† Venoferw; Vifor, St Gallen, Switzerland, 2 £ 200 mg=week:
‡ For details of subjects and procedures, see pp. 5–6. T
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Postpartum
We present the pooled data from four different randomized
studies with Fe–sucrose (Venoferw, Vifor) at cumulative
doses of 100–800 mg given as a single dose (100 mg,
group 1), on 2 d (group 2, 2 £ 200 mg), and on 4 d
(groups 3 and 4, 4 £ 200 mg) (Breymann et al. 1996,
2000). Following mean blood loss of 840 (range 300–
3600) ml, postpartum Hb ranged from 73 (SD 9) to 88
(SD 0·8) g/l before treatment. Overall response at 14 d
(Table 2) showed a dose-dependent increase in Hb (by
21–32 g/l) to normal levels in all groups (Fig. 3); the maxi-
mum mean daily increase in group 4 was 0·23 g/l.
In contrast with the pregnancy results, the red cell indi-
ces showed clear changes only in mean corpuscular
volume; mean corpuscular Hb increased significantly
only in group 4. Interestingly, hypochromic red cells
increased in all groups, especially group 4 with the
Fig. 1. Reponse of haemoglobin to parenteral iron–sucrose complex (Venoferw; Vifor, St Gallen,
Switzerland) in pregnancy anaemia resistant to oral iron therapy (n 100). For details of subjects and pro-
cedures, see pp. 5–6. Values are means with standard deviations shown by vertical bars. Mean values
were significantly different from those at time 0: **P,0·01.
Fig. 2. Response of serum ferritin to parenteral iron–sucrose complex (Venoferw;
Vifor, St Gallen, Switzerland) in pregnancy anaemia resistant to oral iron therapy (n
100). For details of subjects and procedures, see pp. 5–6. Values are means with
standard deviations shown by vertical bars. Mean values were significantly different
from those at time 0: **P,0·01.
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lowest initial Hb, suggesting persistent functional Fe
deficiency in the presence of forced erythropoiesis. Trans-
ferrin saturation and serum ferritin (Fig. 4) increased dose-
dependently to high-normal values in all groups.
Discussion
Although Fe is perhaps the most important heavy metal
in man, and its absorption and metabolism have been
Fig. 3. Response of haemoglobin to parenteral iron–sucrose complex (Venoferw; Vifor, St Gallen,
Switzerland) at four different dosage regimens in postpartum anaemia (n 400). For details of subjects
and procedures, see pp. 5–6 and Breymann et al. (1996, 2000). B, 1 £ 100 mg; A 2 £ 200 mg; V, 4 £
200 mg; S, 4 £ 200 mg: Mean values were significantly different from those 24–48 h postpartum;
**P,0·01.
Fig. 4. Response of serum ferritin to parenteral iron–sucrose complex (Venoferw; Vifor, St Gallen,
Switzerland) at four different dosage regimens in postpartum anaemia (n 400). For details of subjects
and procedures, see pp. 5–6 and Breymann et al. (1996, 2000). B, 1 £ 100 mg; A, 2 £ 200 mg; V,
4 £ 200 mg; S, 4 £ 200 mg: Mean values were significantly different from those at 24–48 h postpar-
tum: **P,0·01.
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intensively researched for some 40 years, many questions
remain unanswered. In particular, the worldwide problem
of Fe deficiency has not yet been solved. Despite the com-
plexity of Fe chemistry and the processes of Fe absorption
and metabolism, we must continue to strive for an even
more detailed understanding of the function of this vitally
important metal.
The consequences of Fe deficiency and Fe deficiency
anaemia are serious, and include reduced exercise toler-
ance, stomatitis, gastritis, structural and chemical changes
to the hair, nails and skin, and impairment of thermogen-
esis, thyroid metabolism and catecholamine turnover. Fe-
deficiency anaemia during pregnancy may result in low
birth-weight and increased preterm birth rate and perinatal
mortality. Fe deficiency in the fetus may lead to sometimes
irreversible damage to the central nervous system, with
impairment of psychomotor development. The prevalence
of Fe-deficiency anaemia in different regions of the
world ranges from 12 to 43 %.
Increased Fe requirement in pregnancy and the puerper-
ium carries with it an increased susceptibility to Fe
deficiency and Fe-deficiency anaemia. Prevention and
correction presuppose reliable laboratory variables and
a thorough understanding of the mechanisms of Fe
therapy. The Hb level alone is insufficient for informing
management.
A complete work-up (ferritin, transferrin saturation) is
essential, preferably with haematological indices such as
hypochromic and microcytic red cells, and reticulocytes,
classified by degree of maturity, in particular before parent-
eral therapy.
Since ferritin acts as both an Fe storage and acute-phase
protein, it cannot be used to evaluate Fe status in the pre-
sence of inflammation. A high ferritin level thus requires
an inflammatory process to be eliminated before it can be
taken at face value. If the C-reactive protein level is also
raised, the soluble TfR concentration can now be used,
since it is unaffected by inflammation.
As Fe balance is regulated by gastrointestinal absorption
and by Fe lost through cell desquamation in the small
intestine (Umbreit et al. 1998), and because free, i.e.
non-protein-bound, Fe is potentially toxic, oral Fe adminis-
tration is normally the treatment of choice. It is effective,
safe and cheap, and subject to the natural regulatory mechan-
ism. In exceptional cases, such as inadequate gastro-
intestinal absorption, poor toleration of the necessary Fe
dose, when a rapid effect is required or to avoid blood
transfusion, intravenous Fe administration is indicated.
Inadequate understanding of the complex chemistry of
parenteral Fe administration was previously responsible
for serious side effects, such as toxic and allergic reactions,
and even anaphylactic shock, in particular with dextran
preparations. This created a somewhat negative attitude
to intravenous Fe therapy which persists to this day.
However, the current type II Fe complexes that release
Fe to the endogenous Fe-binding proteins with a half-life
of about 6 h are not only effective but carry a minimal
risk of allergic accident and overload, especially after a
comprehensive pretreatment work-up (Macdougall et al.
1989; al-Momem et al. 1996; Danielson et al. 1996; Brey-
mann, 1998; Danielson, 1998; Krafft et al. 2000; Rohling
et al. 2000). Our departmental results over 8 years
backed by post-marketing experience in twenty-five
countries indicate that Fe–sucrose complex therapy is a
valid first-line option for the safe and rapid reversal of
Fe-deficiency anaemia.
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